Simcere Pharmaceutical Group Limited (Simcere Pharma) disclosed that it repurchased 1.97 million ordinary shares on 26 March 2026 through on-market transactions at prices ranging between HKD 10.9444 and HKD 11.3272, for a total consideration of HKD 22.03 million.

The latest buyback represents 0.08% of Simcere Pharma’s issued share capital of approximately 2.60 billion shares. All repurchased shares are intended for cancellation.

Including previous repurchases on 12 January, 16 January, 20 January and 22 January, the company has bought back 12.83 million shares under its current mandate, equivalent to 0.52% of the shares outstanding when the mandate was approved on 13 June 2025. The mandate authorises Simcere Pharma to repurchase up to 247.47 million shares.

No new shares were issued during the period, leaving the company’s issued share count unchanged at about 2.60 billion. A 30-day moratorium on new share issues or treasury-share sales is in effect until 25 April 2026, in accordance with Hong Kong Stock Exchange regulations.